


What is claimed is:

1. A compound of Formula (I)




including salts, solvates, and pharmaceutically acceptable derivatives thereof,

wherein A is H, alkyl, or aryl;

R<sup>1</sup> is D<sup>1</sup>, D<sup>2</sup>, D<sup>3</sup>, D<sup>4</sup>, or D<sup>5</sup>,

wherein D<sup>1</sup> is



and R<sup>3</sup> and R<sup>4</sup> are each independently H, alkyl, alkylsulfonyl, or -C(O)-(CH<sub>2</sub>)<sub>x</sub>-R<sup>5</sup>,

where R<sup>5</sup> is alkyl, acyl, alkoxy, -(O)-(CH<sub>2</sub>)<sub>x</sub>-(O)-alkyl, or -NR<sup>6</sup>R<sup>7</sup>,

where R<sup>6</sup> and R<sup>7</sup> are each independently H or alkyl, or


R<sup>6</sup> and R<sup>7</sup> combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing

BEST AVAILABLE COPY

one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, acyl, alkoxy, or halogen,

or R<sup>3</sup> and R<sup>4</sup> combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, alkoxy, acyl, or halogen;

wherein D<sup>2</sup> is




and R<sup>8</sup> is alkyl, or -NR<sup>9</sup>R<sup>10</sup>,

where R<sup>9</sup> and R<sup>10</sup> are each independently selected from H, alkyl, or -(CH<sub>2</sub>)<sub>x</sub>-NR<sup>6</sup>R<sup>7</sup>,

where R<sup>6</sup> and R<sup>7</sup> are each independently H or alkyl,

or R<sup>6</sup> and R<sup>7</sup> combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, acyl, alkoxy, or halogen;

wherein D<sup>3</sup> is



and

the dashed line represents an optional double bond;

when  $R^{11}$  is  $-(CH_2)_x$ , the optional dashed double bond does not exist, and  $R^{12}$  is alkylsulfonyl or  $-NR^{13}R^{14}$ ,


where  $R^{13}$  and  $R^{14}$  are each independently selected from H, alkyl,  $-(CH_2)_x-R^{17}$ , where  $R^{17}$  is alkoxy or  $-NR^{15}R^{16}$ ,

where  $R^{15}$  and  $R^{16}$  are each independently H or alkyl,

or  $R^{13}$  and  $R^{14}$  combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl or  $-(CH_2)_x-OH$ ;

when  $R^{11}$  is  $-(CH)-$ , the optional dashed double bond exists, and  $R^{12}$  is  $-(CH)-C(O)-OH$ ;

wherein  $D^4$  is



and  $R^{17}$  is hydroxy, alkoxy, or  $-NR^{18}R^{19}$ ,

where  $R^{18}$  and  $R^{19}$  are each independently selected from H, alkyl,  $-(CH_2)_x-R^{20}$ ,

where  $R^{20}$  is alkylsulfonyl, hydroxy, aryl said aryl optionally substituted with hydroxy or alkoxy, heteroaryl, or  $-NR^{21}R^{22}$ ,

where  $R^{21}$  and  $R^{22}$  are each independently selected from H, acyl, alkyl,

or  $R^{21}$  and  $R^{22}$  combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted with alkyl or  $-(CH_2)_x-OH$ ;

or  $R^{18}$  and  $R^{19}$  combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted with  $-(CH_2)_x-R^{23}$ ,

where  $R^{23}$  is alkoxy, hydroxy,  $-C(O)-R^{24}$ , where  $R^{24}$  is a 5- or 6-membered ring optionally containing one or more heteroatoms and optionally containing one or more degrees of unsaturation, or  $-NR^{25}R^{26}$ , where  $R^{25}$  and  $R^{26}$  are each independently H or alkyl;

wherein  $D^5$  is

a 5- or 6- membered ring, optionally containing one or more heteroatoms, optionally containing one or more degrees of unsaturation, optionally fused with an additional 5- or 6- membered ring that optionally contains one or more heteroatoms and optionally contains one or more degrees of unsaturation,

wherein the ring or fused ring system may be optionally substituted one or more times with halogen, alkyl, haloalkyl, alkylsulfonyl, alkylthio, hydroxy, alkoxy, oxo, sulfonyl, sulfate ion, nitro, cyano, carboxy, alkoxycarbonyl, aryl where said aryl may be optionally substituted with sulfamoyl, heteroaryl where said heteroaryl may be optionally substituted with alkyl, or  $-NR^{27}R^{28}$ ,

where  $R^{27}$  and  $R^{28}$  are each independently H, alkyl, acyl, alkoxy, alkoxycarbonyl, carboxy, or  $-(CH_2)_x-NR^{29}R^{30}$ , where  $R^{29}$  and  $R^{30}$  are each independently selected from H and alkyl,

or  $R^{27}$  and  $R^{28}$  combine to form a 5- or 6- membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, acyl, alkoxy, or halogen,

or  $-(O)_y-(CH_2)_x-R^{31}$ , where  $R^{31}$  is hydroxy, alkoxy, haloalkyl, aryl optionally substituted with halogen, or  $-NR^{27}R^{28}$ , where  $R^{27}$  and  $R^{28}$  are as defined above;

wherein for each occurrence, x independently is 0, 1, 2, or 3;

wherein for each occurrence, y independently is 0 or 1; and

$R^2$  is phenyl, substituted one or more times with alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, nitro, or  $-NR^{31}R^{32}$ ,

wherein  $R^{31}$  and  $R^{32}$  are each independently selected from H, alkyl, acyl, or  $-(CH_2)_z-R^{33}$ ,


where z is 0, 1, or 2;

and  $R^{33}$  is cycloalkyl.

2. The compound of claim 1 wherein  $R^1$  is  $D^5$ .
3. The compound of claim 2 wherein  $D^5$  is pyridyl.
4. The compound of claim 3, wherein  $D^5$  is 4-pyridyl.
5. The compound of claim 1 wherein  $R^2$  is phenyl substituted with alkoxy.

6. The compound of claim 5 wherein the alkoxy is methoxy.

7. The compound of claim 6 wherein R<sup>2</sup> is



8. The compound of claim 1 wherein for each occurrence, said alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl.

9. The compound of claim 1 wherein R<sup>1</sup> is D<sup>3</sup> and R<sup>11</sup> and R<sup>12</sup> combine to form  
-(CH)=CH)-C(O)-OH.

10. The compound of claim 9 wherein the stereochemical configuration is *cis*.

11. The compound of claim 9 wherein the stereochemical configuration is *trans*.

12. The compound of claim 1 wherein A is H.

13. The compound of claim 1 wherein A is alkyl.

14. The compound of claim 13 wherein A is C<sub>1-6</sub> alkyl.

15. The compound of claim 14 wherein A is selected from propyl or isopropyl.

16. A pharmaceutical composition comprising:  
a therapeutically effective amount of a compound as claimed in claims 1 to 15.


17. The pharmaceutical composition of claim 16 further comprising:  
one or more of pharmaceutically acceptable carriers, diluents, or excipients.

18. A method of treating a disorder in a mammal, said disorder being characterized by misregulation of one or more protein kinase comprising:  
administering to said mammal a therapeutically effective amount of a compound as claimed in claims 1 to 15.
19. The method of claim 18 wherein the kinase is a serine/threonine kinase.
20. The method of claim 19 wherein the kinase is GSK3.
21. The method of claim 18 wherein the kinase is a tyrosine kinase.
22. The method of claim 21 wherein the kinase is TIE2.
23. A method of treating a disorder in a mammal, said disorder being characterized by misregulation of one or more protein kinase, comprising:  
administering to said mammal a therapeutically effective amount of a compound as claimed in claims 1 to 15.
24. The method of claim 23 wherein the protein kinase is GSK3.
25. The method of claim 23 wherein the protein kinase is TIE2.
26. A compound as claimed in claims 1 to 15 for use in therapy.
27. Use of a compound as claimed in claims 1 to 15 in the preparation of a medicament for use in the treatment of a disorder characterized by misregulation of one or more protein kinase.

28. A method of treating type 2 diabetes, hyperlipidemia, obesity, CNS disorders, neurotraumatic injuries, immune potentiation, baldness or hair loss, atherosclerotic cardiovascular disease, hypertension, polycystic ovary syndrome, ischemia, immunodeficiency, and cancer, comprising:  
administering to said mammal a therapeutically effective amount of a compound as claimed in claims 1 to 15.
29. A method of treating type II diabetes, comprising:  
administering to said mammal therapeutically effective amounts of
- (i) a compound as claimed in claims 1 to 15; and
  - (ii) at least one additional anti-diabetic agent.
30. A compound according to any of claims 1 to 15 with reference to any of the Examples.



31. A compound of Formula (II):



including salts, solvates, and pharmaceutically functional derivatives thereof,

where A is H, alkyl, or aryl;

R<sup>a</sup> is alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, nitro, or -NR<sup>b</sup>R<sup>c</sup>,


wherein R<sup>b</sup> and R<sup>c</sup> are each independently selected from H, alkyl, acyl, or -(CH<sub>2</sub>)<sub>z</sub>-R<sup>d</sup>,

where z is 0, 1, or 2; and

R<sup>d</sup> is cycloalkyl.

295

32. A compound of formula (III)



including salts, solvates, and pharmaceutically functional derivatives thereof,

where A is H, alkyl, or aryl;


$R^a$  is alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, nitro, or  $-NR^bR^c$ ,

wherein  $R^b$  and  $R^c$  are each independently selected from H, alkyl, acyl, or  $-(CH_2)_z-$   
 $R^d$ ,

where z is 0, 1, or 2; and

$R^d$  is cycloalkyl.

33. A compound of formula (IV)



including salts, solvates, and pharmaceutically functional derivatives thereof,

where A is H, alkyl, or aryl;


$R^a$  is alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, nitro, or  $-NR^bR^c$ ,

wherein  $R^b$  and  $R^c$  are each independently selected from H, alkyl, acyl, or  $-(CH_2)_z-$   
 $R^d$ ,

where  $z$  is 0, 1, or 2; and

$R^d$  is cycloalkyl.

34. A compound of formula (V)



including salts, solvates, and pharmaceutically functional derivatives thereof,

where  $A$  is H, alkyl, or aryl;

$R^a$  is alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, nitro, or  $-NR^bR^c$ ,

wherein  $R^b$  and  $R^c$  are each independently selected from H, alkyl, acyl, or  $-(CH_2)_z-$   
 $R^d$ ,

where  $z$  is 0, 1, or 2;

$R^d$  is cycloalkyl; and

$R^e$  is H or  $-C(O)-(O)-C-(CH_3)_3$ .

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**